Cefazolin as empiric therapy in hemodialysis-related infections: Efficacy and blood concentrations

American Journal of Kidney Diseases

Volumn 32, Issue 3, 1998, Pages 410-414

  Marx, Michael A ^a,b   Frye, Reginald F ^c   Matzke, Gary R ^c   Golper, Thomas A ^c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c NONE

Author keywords

Antibiotic resistance; Cefazolin; Empiric drug therapy; Hemodialysis infections

Indexed keywords

CEFAZOLIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; FEMALE; HEMODIALYSIS; HUMAN; INFECTION RISK; MALE; STAPHYLOCOCCUS INFECTION;

EID: 0031660854     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.1998.v32.pm9740156     Document Type: Article

References (20)

1. Keane WF, Alexander SR, Bailie GR, Boeschoten E, Gokal R, Golper TA, Holmes CJ, Huang C-C, Kawaguchi Y, Piraino B, Riella M, Schefer F, Vas S: Peritoneal dialysis-related peritonitis treatment recommendations: 1996 Update. Perit Dial Int 16:557-573, 1996
2. Edmond MB, Wenzel RP, Pasculle AW: Vancomycin-resistant Staphylococcus aureus: Perspectives on measures needed for control. Ann Intern Med 124:329-334, 1996
3. Gin AS, Zhanel GO: Vancomycin-resistant enterococci. Ann Pharmacother 30:615-624, 1996
4. Centers for Disease Control and Prevention: Preventing the spread of vancomycin resistance - Report from the Hospital Infection Control Practices Advisory Subcommittee. Fed Reg 59:25757-25763, 1994
5. Centers for Disease Control and Prevention: Recommendations for the prevention and spread of vancomycin resistance. MMWR Morb Mortal Wkly Rep 44:1-13, 1995
6. Recommendations for preventing the spread of vancomycin resistance: Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Am J Infect Control 23:87-94, 1995
7. US Centers for Disease Control: Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan, 1996. MMWR Morb Mortal Wkly Rep 46:624-626, 1997
8. US Centers for Disease Control: Staphylococcus aureus with reduced susceptibility to vancomycin - United States. MMWR Morb Mortal Wkly Rep 46:765-766, 1997
9. Strausbaugh LJ, Bennett WM: Should vancomycin use in dialysis patients be restricted? Semin Dial 9:235-237, 1996
10. Edmiston CE Jr: Vancomycin resistance: When failure becomes an opportunity for leadership. Ann Pharmacother 30:680-682, 1996
11. Golper TA, Tranaeus A: Vancomycin revisited. Perit Dial Int 16:116-117, 1996
12. US Centers for Disease Control: Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Wkly Rep 46:626-635, 1997
13. Bechtel TP, Slaughter RL, Moore TD: Seizures associated with high cerebrospinal fluid concentrations of cefazolin. Am J Hosp Pharm 37:271-273, 1980
14. Schwankhaus JD, Masucci EF, Kurtzke JF: Cefazolin-induced encephalopathy in a uremic patient. Ann Neurol 17:211, 1985
15. Josse S, Godin M, Fillastre JP: Cefazolin-induced encephalopathy in a uraemic patient. Nephron 45:72, 1987
16. Craig WA, Welling PG, Jackson TC, Kunin CM: Pharmacology of cefazolin and other cephalosporins in patients with renal insufficiency. J Infect Dis 128:S347-S353, 1973 (suppl)
17. McCloskey RV, Forland MF, Sweeney MJ, Lawrence DN: Hemodialysis of cefazolin. J Infect Dis 128:S358-S360, 1973 (suppl)
18. Brogard JM, Pinget M, Brandt C, Lavillaureix J: Pharmacokinetics of cefazolin in patients with renal failure; Special reference to hemodialysis. J Clin Pharmacol 4:225-230, 1977
19. Schulman G, Hakim RM: Improving outcomes in chronic hemodialysis patients: Should dialysis be initiated earlier? Semin Dial 9:225-229, 1996
20. National Kidney Foundation-Dialysis Outcomes Quality Initiative (NKF-DOQI) Clinical Practice Guidelines: Initiation of dialysis. Am J Kidney Dis 30:S70-S73, 1997 (suppl 2)